Form 4: Emergent BioSolutions CFO's Options Expire Unexercised
Insider Transaction Report
Emergent BioSolutions' EVP and CFO, Richard S. Lindahl, reported the expiration of unexercised employee stock options and a late Form 4 filing.
Summary
- Richard S. Lindahl, Executive Vice President and Chief Financial Officer of Emergent BioSolutions Inc. (EBS), filed a Form 4.
- The filing reports the expiration of two tranches of employee stock options without value received.
- One tranche for 19,963 shares with an exercise price of $48.33 expired on May 7, 2025.
- Another tranche for 20,321 shares with an exercise price of $61.01 expired on February 25, 2026.
- The Form 4 was filed late due to an inadvertent administrative error.
Sentiment
Score: 3
Explanation: StockSavvy.ai views this filing negatively due to the expiration of a significant number of executive stock options without value received, coupled with a late filing indicating a compliance oversight.
Negatives
- Employee stock options for 19,963 shares (exercise price $48.33) and 20,321 shares (exercise price $61.01) expired unexercised, meaning the holder received no value.
- The Form 4 was filed late due to an inadvertent administrative error.
Risks
- Inadvertent administrative errors in SEC filings can indicate potential weaknesses in internal compliance procedures.
Future Outlook
The company plans to report all late Form 4 filings in its next proxy statement.
Management Comments
- The reported stock options expired unexercised pursuant to their terms and no value was received.
- This Form 4 was filed late due to an inadvertent administrative error.
Industry Context
StockSavvy.ai notes that Form 4 filings are routine disclosures of insider transactions, and the expiration of unexercised options typically reflects that the company's stock price remained below the option's strike price during its term, which is not uncommon in volatile markets or for long-dated options.
Comparison to Industry Standards
- NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compliance Issue | The Form 4 was filed late due to an inadvertent administrative error, indicating a lapse in timely regulatory reporting. | 03/06/2026 | Could raise minor concerns regarding internal controls and compliance procedures, though the company has committed to reporting all late filings in its next proxy statement. |
Stakeholder Impact
- Shareholders may view the late filing as a minor governance concern.
- The expiration of options without value could be seen as a neutral to slightly negative signal regarding past stock performance relative to option strike prices.
Next Steps
- The company will report all late Form 4s in its next proxy statement.
Key Dates
| Date | Description |
|---|---|
| 05/07/2019 | First vesting installment for 19,963 options. |
| 05/07/2020 | Second vesting installment for 19,963 options. |
| 05/07/2021 | Third vesting installment for 19,963 options. |
| 05/07/2025 | Expiration date for 19,963 employee stock options with an exercise price of $48.33. |
| 02/25/2026 | Expiration date for 20,321 employee stock options with an exercise price of $61.01. |
| 03/06/2026 | Signature date of the reporting person on the Form 4. |
Keywords
Emergent BioSolutions, EBS, Form 4, Insider Transaction, Stock Options, Executive Compensation, Richard S. Lindahl, SEC Filing, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.